Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for two drugs: Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (30mg per 1ml) [2] Group 1 - The company announced the receipt of drug registration certificates for Nicardipine Tablets and Ketorolac Tromethamine Injection [2]

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs, which will enhance the company's product line [1] Group 1: Drug Approvals - Laimei Pharmaceutical has obtained drug registration certificates for Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, while Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1] Group 2: R&D Investment - The total R&D investment for Nicorandil tablets was approximately RMB 5.39 million, and for Ketorolac Tromethamine injection, it was around RMB 4.74 million [1] - The approval of these drugs is expected to further enrich the company's product offerings [1]

Company Overview - Recently, Laimei Pharmaceutical (SZ 300006, closing price: 4.58 yuan) announced the approval of two drug registration certificates by the National Medical Products Administration for Nicorandil tablets and Ketorolac Tromethamine injection [1] Financial Performance - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] Market Position - As of the report, Laimei Pharmaceutical has a market capitalization of 4.8 billion yuan [1]

Core Viewpoint - Lai Mei Pharmaceutical has received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml: 30mg) [1] Group 1: Drug Approvals - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain [1]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (30mg/1ml) [1] Group 1 - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-046 重庆莱美药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 | 药品名称 | 药品通用名称：酮咯酸氨丁三醇注射液 | | --- | --- | | | 英文名/拉丁名：Ketorolac Trometamol Injection | | 主要成份 | 酮咯酸氨丁三醇 | | 剂型 | 注射剂 | | 规格 | 1ml:30mg | | 证书编号 | 2025S02756 | | 药品注册标准编号 | YBH20742025 | | 包装规格 | 10 支/盒 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 3 类 | | 药品批准文号 | 国药准字 H20255358 | | 药品有效期 | 个月 24 | | 处方药/非处方药 | 处方药 | | 上市许可持有人 | 名称：重庆莱美药业股份有限公司 | | | 地址：重庆市南岸区玉马路 号 99 | | 生产企业 | 名称：重庆莱美药业股份有限公司 | | | 地址：重庆市 ...

Core Viewpoint - The company, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (30mg/1ml) [1] Group 1: Drug Approvals - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain [1]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5 mg) and Ketorolac Tromethamine injection (30 mg per 1 ml) [1] Group 1: Product Approvals - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for two new drug registrations, indicating a positive development in its product pipeline [1] Group 1: Drug Approvals - The company has obtained a drug registration certificate for Nicorandil tablets (5mg), which are indicated for the treatment of angina pectoris [1] - The company has also received approval for Ketorolac Tromethamine injection (1ml: 30mg), which is suitable for short-term treatment of moderate to severe postoperative pain [1]

北京市中伦律师事务所 关于重庆莱美药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年九月 北京市中伦律师事务所 关于重庆莱美药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受重庆莱美药业股份有限公 司（以下简称"公司"）委托，指派律师出席公司 2025 年第一次临时股东大会 （以下简称"本次股东大会"），对本次股东大会的相关事项进行见证并出具法 律意见。 本所及经办律师依据《中华人民共和国证券法》（以下简称"《证券法》"） 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法 定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律 意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在 虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本所律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、《证 券法》、《上市公司股东会规则》（以下简称"《股东会规则》"）及《深圳证 券交易所上市公司股东会网络投票实施细则》等法律、行政法规、规范性文件以 及 ...